Download PDF
Diabetes aktuell 2024; 22(06): 255-262
DOI: 10.1055/a-2401-3920
Schwerpunkt

Diabetische Nephropathie und Progressionsverlangsamung der CKD

Portfolio zur Therapie der diabetischen Nephropathie
Thilo Krüger
1   MVZ DaVita Geilenkirchen GmbH, Geilenkirchen
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Die Verlangsamung des Krankheitsverlaufs bei chronischer Nierenkrankheit (CKD: „chronic kidney disease“) stellt eine wesentliche, wenn nicht die wesentlichste Aufgabe von Nephrologinnen und Nephrologen dar. Aufgrund der Häufigkeit von Diabetes mellitus kommt der diabetischen Nephropathie dabei ein bedeutender Stellenwert zu. Erfreulicherweise haben sich in den letzten Jahren zahlreiche Neuerungen in Bezug auf therapeutische Möglichkeiten ergeben. Dieser Artikel fasst sowohl altbekannte als auch neue Behandlungsmethoden zur Progressionsverlangsamung der diabetischen Nephropathie zusammen.



Publication History

Article published online:
18 October 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Saran R, Robinson B, Abbott KC. et al US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis 2019; 73: A7-A8
    CrossrefPubMedSearch in Google Scholar
  • 2 Cho NH, Shaw JE, Karuranga S. et al IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018; 138: 271-281
    CrossrefPubMedSearch in Google Scholar
  • 3 Brijesh M, Saurav P. Comparative Study of Significance of Serum Cystatin-C, Serum Creatinine and Microalbuminuria Estimation in Patients of Early Diabetic Nephropathy. J Diabetes Metab 2015; 6: 490
    CrossrefSearch in Google Scholar
  • 4 U. S. Dept of Health and Human Services – Centers for Disease Control and Prevention. National Diabetes Statistics Report 2020. Im Internet:. www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf Stand 17.01.2023
  • 5 Johansen KL, Chertow GM, Foley RN. et al US Renal Data System 2020 Annual Data Report: Epidemiology of kidney disease in the United States. Am J Kidney Dis 2021; 77: A7-A8
    CrossrefPubMedSearch in Google Scholar
  • 6 Afkarian M, Zelnick LR, Hall YN. et al Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988–2014. JAMA 2016; 316: 602
    CrossrefPubMedSearch in Google Scholar
  • 7 Sanghavi SF, Roark T, Zelnick LR. et al Histopathologic and Clinical Features in Patients with Diabetes and Kidney Disease. Kidney360 2020; 1: 1217-1225
    CrossrefPubMedSearch in Google Scholar
  • 8 de Zeeuw D.. Albuminuria: A Target for Treatment of Type 2 Diabetic Nephropathy. Semin in Nephrol 2007; 27: 172-181
    CrossrefPubMedSearch in Google Scholar
  • 9 Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857-1863
    CrossrefPubMedSearch in Google Scholar
  • 10 Chapter 1: Definition and classification of CKD. Kidney Int Suppl 2013; 3: 19-62
    CrossrefPubMedSearch in Google Scholar
  • 11 Ames MK, Atkins CE, Pitt B.. The renin-angiotensin-aldosterone system and its suppression. J Vet Intern Med 2019; 33: 363-382
    CrossrefPubMedSearch in Google Scholar
  • 12 Hommel E, Parving HH, Mathiesen E. et al Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J (Clin Res Ed) 1986; 293: 467-470
    CrossrefPubMedSearch in Google Scholar
  • 13 Bjorck S, Nyberg G, Mulec H. et al Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J (Clin Res Ed) 1986; 293: 471-474
    CrossrefPubMedSearch in Google Scholar
  • 14 Heeg JE, de Jong PE, van der Hem GK. et al Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int 1987; 32: 78-83
    CrossrefPubMedSearch in Google Scholar
  • 15 Mittal N, Sehray V, Mittal R. et al Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data. Eur J Pharmacol 2021; 907: 174320
    CrossrefPubMedSearch in Google Scholar
  • 16 Heerspink HJL, Stefánsson BV, Correa-Rotter R. et al Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383: 1436-1446
    CrossrefPubMedSearch in Google Scholar
  • 17 The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 388: 117-127
    CrossrefPubMedSearch in Google Scholar
  • 18 Wanner C, Inzucchi SE, Lachin JM. et al Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375: 323-334
    CrossrefPubMedSearch in Google Scholar
  • 19 Zinman B, Wanner C, Lachin JM. et al Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128
    CrossrefPubMedSearch in Google Scholar
  • 20 Cannon CP, Pratley R, Dagogo-Jack S. et al Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med 2020; 383: 1425-1435
    CrossrefPubMedSearch in Google Scholar
  • 21 Neuen BL, Young T, Heerspink HJL. et al SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2019; 7: 845-854
    CrossrefPubMedSearch in Google Scholar
  • 22 Rossing P, Caramori ML, Chan JCN. et al KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2022; 102: S1-S127
    CrossrefPubMedSearch in Google Scholar
  • 23 Rossing P, Caramori ML, Chan JCN. et al Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int 2022; 102: 990-999
    CrossrefPubMedSearch in Google Scholar
  • 24 de Boer IH, Khunti K, Sadusky T. et al Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022; 45: 3075-3090
    CrossrefPubMedSearch in Google Scholar
  • 25 Singh AK, Singh A, Singh R. et al Finerenone in diabetic kidney disease: A systematic review and critical appraisal. Diabetes Metab Syndr 2022; 16: 102638
    CrossrefPubMedSearch in Google Scholar
  • 26 Bakris GL, Agarwal R, Chan JC. et al Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA 2015; 314: 884
    CrossrefPubMedSearch in Google Scholar
  • 27 Ong GSY, Young MJ. Mineralocorticoid regulation of cell function: the role of rapid signalling and gene transcription pathways. J Mol Endocrinol 2017; 58: R33-R57
    CrossrefPubMedSearch in Google Scholar
  • 28 Sarafidis P, Iatridi F, Ferro C. et al Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA). Clin Kidney J 2023; 16: 1885-1907
    CrossrefPubMedSearch in Google Scholar
  • 29 Bakris GL, Agarwal R, Anker SD. et al Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383: 2219-2229
    CrossrefPubMedSearch in Google Scholar
  • 30 Pitt B, Filippatos G, Agarwal R. et al Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021; 385: 2252-2263
    CrossrefPubMedSearch in Google Scholar
  • 31 Agarwal R, Filippatos G, Pitt B. et al Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022; 43: 474-484
    CrossrefPubMedSearch in Google Scholar
  • 32 Mosenzon O, Schechter M, Leibowitz G.. Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. Adv Chronic Kidney Dis 2021; 28: 347-360
    CrossrefPubMedSearch in Google Scholar
  • 33 Madsbad S.. Treatment of type 2 diabetes with incretin-based therapies. Lancet 2009; 373: 438-439
    CrossrefPubMedSearch in Google Scholar
  • 34 Marso SP, Bain SC, Consoli A. et al Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 1834-1844
    CrossrefPubMedSearch in Google Scholar
  • 35 Shaman AM, Bain SC, Bakris GL. et al Effect of the Glucagon-like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: a Pooled Analysis of SUSTAIN 6 and LEADER Trials. Circulation 2021; 145: 575-585
    CrossrefPubMedSearch in Google Scholar
  • 36 Wanner C, Heerspink HJL, Zinman B. et al Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. J Am Soc Nephrol 2018; 29: 2755-2769
    CrossrefPubMedSearch in Google Scholar
  • 37 Husain M, Birkenfeld AL, Donsmark M. et al Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2019; 381: 841-851
    CrossrefPubMedSearch in Google Scholar
  • 38 Novo Nordisk Pharma GmbH. Im Internet:. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=167028 Stand: 12.03.2024
  • 39 Marso SP, Daniels GH, Brown-Frandsen K. et al Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-322
    CrossrefPubMedSearch in Google Scholar
  • 40 Mann JFE, Ørsted DD, Brown-Frandsen K. et al Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377: 839-848
    CrossrefPubMedSearch in Google Scholar
  • 41 Gerstein HC, Colhoun HM, Dagenais GR. et al Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394: 121-130
    CrossrefPubMedSearch in Google Scholar
  • 42 Gerstein HC, Colhoun HM, Dagenais GR. et al Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. The Lancet 2019; 394: 131-138
    CrossrefPubMedSearch in Google Scholar
  • 43 Mann JFE, Buse JB, Idorn T. et al Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. Diabetes Obes Metab 2021; 23: 2058-2066
    CrossrefPubMedSearch in Google Scholar
  • 44 Holman RR, Bethel MA, Mentz RJ. et al Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377: 1228-1239
    CrossrefPubMedSearch in Google Scholar